What`s New for 2022?

» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year

Global Novel Drug Delivery Systems (NDDS) Market to Reach US$28.1 Billion by the Year 2026

In recent years, the quest for delivering therapeutic agents with enhanced efficacy and minimal side effects has resulted in the proliferation of novel drug delivery systems (NDDS) in the pharmaceutical industry. NDDS refer to new approaches, technologies, formulation, and systems used for the transportation of a pharmaceutical compound inside the body for safely achieving its desired pharmacological effects. Growth in the global market is set to be primarily driven by the benefits offered by controlled-release drug delivery systems, including reduced treatment cost, lower side effects, and enhanced therapeutic efficacy. The growing adoption of controlled-release drugs as a standard treatment for various diseases, rising awareness and demand for advanced products among physicians, and increasing prescription of controlled-release products are some of the key factors that are likely to bolster the market growth in the near future. Further, presence of several in-vivo biological barriers that impacts the drug`s stability, absorption, and bioavailability are opening lucrative opportunities for the adoption of controlled-release drug delivery systems.

The adoption of controlled-release drug delivery systems is also being propelled by the rapidly growing pediatric and geriatric population, owing to high incidence of non-adherence to prescription drugs in these age-groups. Nanotechnology has come to the fore to further enhance the relevance of continuous improvisation and innovation of NDDS, especially for administering active agents. Several terminal diseases such as immunodeficiency diseases and cancers require controlled and targeted therapy with minimum side effects, and for these systems, nanocarrier-based systems deliver a better therapeutic effect at the target site. Currently, the pharmaceutical industry is preparing for widespread adoption of nanoparticles, which represents a crucial element in advanced nanotechnology-enabled delivery systems.

Amid the COVID-19 crisis, the global market for Novel Drug Delivery Systems (NDDS) estimated at US$12.7 Billion in the year 2022, is projected to reach a revised size of US$28.1 Billion by 2026, growing at a CAGR of 20.8% over the analysis period. Nanoparticles, one of the segments analyzed in the report, is projected to grow at a 20.3% CAGR to reach US$27.2 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Embolization Particles segment is readjusted to a revised 22.9% CAGR for the next 7-year period. This segment currently accounts for a 17.3% share of the global Novel Drug Delivery Systems (NDDS) market. The rising uptake of nanotechnology and its various concepts including nanocarriers in novel drug delivery mechanisms is driving growth in the Nanoparticles segment. The use of nanoparticles in delivering drugs to cancer cells with minimum damage to healthy cells is the most promising application of nanotechnology in drug delivery currently under development.

The U.S. Market is Estimated at $120.5 Million in 2022, While China is Forecast to Reach $50.7 Million by 2026

The microRNA (miRNA) market in the U.S. is estimated at US$120.5 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$50.7 Million by the year 2026 trailing a CAGR of 17.7% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.1% and 13% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.5% CAGR. The North American region dominates the global market, owing to technological advances, government support, and excellent medical reimbursement facilities. Ever-increasing clinical trials seeking to develop novel diagnostics and therapeutics, particularly in the US, is another key growth driver. Growth in the Europe market is because of increased funding towards research in countries like Germany to encourage the entry of startups in the molecular diagnostics industry, particularly in microRNA. The microRNA market in Asia Pacific is likely to gain considerable momentum due to increasing consumer awareness, rapid growth in population, supportive government policies, healthcare infrastructure modernization, and escalating foreign investments in developing nations like India and China in the regional market. The Asia Pacific region will also be driven by advances in proteomics and genomics along with increasing adoption of novel tools that help meet research goals.